Categories
CEO & Collaborators Gonorrhea Medical Sexually Transmitted Infections

Why Hygee is important now: The Medical Case

We can start with a basic reality. The incidence of Sexually Transmitted Infections (STI) has reached epidemic proportions. This epidemic has serious implications for people and for our society, and they fall into two categories: health and economic. In this blog post, I’m going to talk about the effects on health, and I’ll talk about money and business next post.

There are a lot of STI. Some STI are viral, some caused by parasites, and some are bacterial. Bacterial infections are the most easily treatable because we have antibiotics for them. There are four major bacterial STI: chlamydia, gonorrhea, syphilis, and trichomoniasis. In the United States alone, the Centres for Disease Control reported this past August* that between 2013 and 2017 the number of people infected has increased greatly.

  • Chlamydia is the most common STI More than 1.7 million cases were diagnosed in 2017, 45% in 15- to 24-year-old women.
  • Gonorrhoea diagnoses increased 67% overall to 555,608 new infections in 2017, and nearly doubled among men (from 169,130 to 322,169). Infections in women increased in 2017 for the third year in a row.
  • Syphilis diagnoses increased 76%, although overall the numbers for this infection are much smaller than the other two.
  • The CDC did not report figures for trichomoniasis, but we can easily assume that the number of infections is growing rapidly as well,

Worldwide, the numbers are alarming, yet I have to point out, that the Americas, which include, Canada and the United States, two countries that invest a huge amount of money in modern healthcare systems, show higher rates of chlamydia and trichomoniasis than any other region.

As I said, all of these are curable with antibiotics, yet most cases aren’t diagnosed and aren’t treated. Untreated chlamydia can have severe effects on women and on the babies of untreated women. These include infertility, ectopic pregnancies, babies born blind or stillborn, and increased HIV risk.

New research suggests that one or two strains of chlamydia can also morph into trachoma, a tropical disease, which can cause blindness in the woman herself.

Why is this happening? Why do STI go undiagnosed and untreated, even in First World countries? There is a stigma around STI. People who are infected are shamed, and looked down on. Especially young woman who may be afraid to access medical help because their parents might be informed. In the US, healthcare is still subject to socioeconomic factors like poverty and access to clinics.

Hygee is important because it gives women the tool they need to get diagnosed on their own. A girl or woman will be able to buy the kit from a pharmacy or order it online. All she has to do is wear the pad for a minimum of four hours, put the pad in the envelope, tear off the envelope’s tab, and put it in the mail. The ETST partner lab will do the testing. She never puts her name on the test; there is just a number on the pad, the envelope, and the tab she keeps. A few days later, she can go online or phone the lab toll-free. She uses the number on the tab to access her results. If she is not infected, then no one will ever know she even decided to get tested.

If she is infected, the lab or the website will tell her what to do. She will have to see a doctor to get the antibiotics she needs to talk to kill the infection. She will have to be sure not to have unprotected sex until she has finished her course of antibiotics, and hardest of all, she should inform her partner(s) that she was infected that they have to get tested and treated as well. That is not so private, but it’s the only way to stop the spread of the disease.

Hygee will make it easy and private for women to get tested, and improved access to testing is the first step in stemming this massive, destructive epidemic.

The costs of STI infections aren’t just human health they are also economic. Next time.

Categories
Cannabinoids Cannabis Oils Cannabis Plant CEO & Collaborators Hemp Oil Industrial Hemp Medical

Human Studies on Cannabidiol as a Treatment for Anxiety

Medical research shown shown that a chemical produced by the cannabis sativa plant reduces anxiety. This constituent of cannabis is called cannabidiol, or just CBD.

Cannabis has many constituents, but by far the most well known is tetrahydrocannabinol, or THC, the constituent which gets the user ‘high’. CBD however, has completely different effects from THC and is becoming more and more popular as multiple studies suggest that this substance is an anxiolytic, which means that it reduces anxiety and panic. CBD also diminushed the psychoactivity of THC, meaning that it can helps people that are using medical marrijuana to counter the unwanted “high” associate with THC present in that treatments.

CBD was discovered in 1940 by Dr. Roger Adams at the University of Illinois. At that time, cannabis was only known for its psychotropic constituent THC, so studies were mainly focused there. As a result, there was little done to explore and study the effects of CBD for many years. More recently, studies on CBD have been done first on animals and then on humans to determine exactly what CBD does in the body. Medicine has discovered that CBD does have many medicinal benefits, and we are starting to hear about them.

One of the pioneer study in 1993 compared CBD with Ipsapirone, diazepam and a placebo. Ipsapirone is an anxiolytic drug often used in research. Diazepam is a drug used to reduce anxiety in patients by working on chemicals in the brain that are unbalanced in people who suffer from anxiety. The study tested the different drugs and CBD on a set of healthy people. The subjects were subjected to a simulated public speaking test in order to create a stressful environment in which scientists could verify if CBD was anxiolytic. By measuring subjects’ heart ratea, blood pressure and skin conductance, the study showed that only Ipsapirone decreased anxiety during public speaking, CBD decreased anxiety that occurred after the test, and diazepam was effective before and after the test, but not during the test. The study suggested that CBD and Ipsapirone had anxiolytic properties.

A more recent study in 2004 investigated the effects of CBD on regional cerebral blood flow by doing single-photon emission computed tomography (SPECT) scans on the subjects. This scan gives doctors three pieces of information: areas of the brain that work well, areas of the brain that are low in activity, and areas that are high in activity. Doctors can then determine if the subject needs specific medicine to regulate certain areas that need to be balanced. Since in this case study, the test itself was stressful, it was a good way to test CBD. The results showed that CBD reduced anxiety, according to blood flow, and was compatible with regular blood flow.

In more than one study, it was also discovered that the effects of dosage levels act in a U-shaped curve. Small dosages of 100mg of CBD were ineffective, dosages of 300mg to 600mg were most effective and treatments over 900mg of CBD were also ineffective.

In 2009, another study made the use of functional magnetic resonance imaging (FMRI), which produces more images with higher resolution and gives a clearer image of the levels of activity in the brain, to see if CBD had anxiolytic effects. They tested 15 healthy people and the results showed that CBD did reduce the anxiety caused by the stress of the FMRI.

A Brazilian study done in 2010 found that Cannabidiol has therapeutic potential with antipsychotic, anxiolytic, and antidepressant properties, in addition to being effective in treating other conditions on subjects with psychiatric disorders and in healthy subjects. These findings suggest that CBD may be effective is treating patients with anxiety as a mental illness.

 

Categories
Feature Story Gonorrhea In the News Latest News Marketing Medical Sexually Transmitted Infections Top Stories

Earth Science Tech LTD (ETST) Promotes Women’s Health with Strategically Branded Self-sampling Kit

DORAL, Florida, Oct. 09, 2018 (GLOBE NEWSWIRE) —

Earth Science Tech LTD (OTCQB: ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today details its branding strategy for Hygee™, a medical device designed for the detection of sexually transmitted infections (STIs) in women. With plans to market Hygee™ on five continents, ETST is deploying a striking graphic identity that will speak directly to women.

“From the name of the device to specifics of the logo, our branding strategy reflects the personal yet crucial nature of the Hygee™ self-sampling kit. We wanted to make the brand memorable, yet simple enough to promote its ease-of-use,” states Nickolas S. Tabraue, president, director and chairman of ETST. “Hygee™ is associated with peace of mind, protection, security, health and wellness.”A play on the Greek word for “hygiene,” the name Hygee™ integrates intimacy, confidentiality and discretion. Hygee™ looks like – and is worn like – a standard panty liner. Aptly named, the device allows a woman to discreetly take her own sample for testing to detect STIs, starting with chlamydia.

The positioning of “Personal feminine health test” explains the purpose of the product. Set under the logo, it gives the target market the context needed to better understand the brand.

The tagline, “Accurate, Simple and Discreet,” reflects the personal nature of the product.

ETST CEO and Chief Science Officer Dr. Michel Aubé said, “Hygee™ is designed to preserve women’s health. Our goal is to act upstream to give women the control and the information they need to avoid severe health complications from STI.”

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/3330935c-ad09-415b-b662-94d805e17ceb

The Market

While STIs are a serious problem worldwide, the rates of infection across the USA have increased for the third consecutive year, according to the Centers for Disease Control and Prevention. The market for Hygee™ is considerable, as no one uses this technology to perform the 100 million tests for Chlamydia trachomatis done around the world each year. ETST believes Hygee™ will be an ideal tool for high throughput screening of individuals who want to know if they are infected with STIs like chlamydia and gonorrhea. It is accepted that young women are also at higher risk, and this is why ETST will market Hygee™ to target that demographic.

“The best way to fight STIs is prevention, and the only way for women to avoid the dangerous results of untreated STI is early treatment. This means that women need to know if they are infected. We believe that Hygee™ will be the best tool to provide that information. ETST will target specific populations of women globally to better counter the STI epidemic,” said Dr. Aubé.

About Earth Science Tech LTD (ETST)

Earth Science Tech LTD (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market.. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.

To learn more, please visit: www.earthsciencetech.com

Categories
Cannabinoids Cannabis Science Hemp Oil Latest News Medical Science Top Stories

The Entourage Effect: the Essence of Synergy

There are hundreds of natural components found in cannabis, 66 alone which are classified as unique to the plant. And although there is no disputing the profound and positive impact on the body’s receptor system, scientists are still trying to figure out exactly how those chemical compounds interact with each other and with the human body. What we do know is that cannabinoids affect many important functions in the endocannabinoid system in our bodies. CBD for instance has pain relieving, antioxidant, anti-inflammatory and anti-nausea effects, while CBDV has been shown to be helpful in the management of epileptic seizures and CBC has antifungal and anticonvulsant properties– and so on. Most fascinating though is the research around the cannabis plant’s interaction with itself and how when certain isolated components are combined together, they produce a greater more tangible benefit to the user. This interactive synergy is known as the entourage effect.

The synergistic effect between compounds is nothing new. Traditional Chinese practitioners have been treating specific problems with herb concoctions for centuries. The concept, while not exact, is similar to the way the entourage effect works. The term “entourage effect” was first used decades ago by two Israeli scientists Shimon Ben-Shabat and Raphael Mechoulam. They realized that cannabinoids found in the cannabis plant actually work in a similar way as the body’s own endocannabinoid system- which is to say that each cannabinoid has a different and beneficial effect in our body. In this specific study it was the cannabinoid tetrahydrocannabinol (THC) which was responsible for those benefits but the same patients also reported a heightened psychotropic effect which made them feel “stoned”.  Since Cannabidiol (CBD) is known to modulate the effect of THC on the human body, the same dose was blended with it resulting in that same patient group reporting the same benefits minus the unwanted side effect of the THC.

While researchers agree that more studies are needed to understand the entourage effect, many can attest that the heightened efficacy when compounds operate together is real and not imagined.  Not only can this be seen between CBD and THC but also in how terpenes and flavonoids increase the cerebral blood flow, impacting the blood-brain barrier; another way in which cannabinoids work together.  Everyone agrees that as a whole we have only begun to scratch the surface and that the field is wide open for greater exploration and development.

Categories
Cannabis Oils Drug Addiction Hemp Oil In the News Latest News Medical Opioid Addiction Press Releases

Earth Science Tech Finalizes Plans for Human Trials on New CBD-Based Formula Targeting Opioid Addiction Epidemic

Doral, FL, February 28, 2018 (GLOBE NEWSWIRE) – Earth Science Tech (OTC PINK: ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabinoid (CBD), nutraceutical and pharmaceutical fields, as well as on R&D for certain medical devices, today announced it has finalized plans for a 9-month human trial to assess the efficacy of its treatment combining an essential mineral element and full-spectrum cannabinoid industrial hemp oil. This is expected to increase potency as opposed to the status quo in the market today, which consists solely of essential mineral element therapy (monotherapy) in treating patients with morbid substance abuse and/or dependence. These plans were originally announced in late 2017. The purpose of this trial is to develop a methodology for treating opioid addicts, preventing fatal overdoses, and relieving side-effects from withdrawals.

The new study takes advantage of two of the properties of ETST’s full-spectrum cannabinoids industrial hemp oil that have already shown great success against addiction, based on positive feedback from customers and doctors alike. The full-spectrum cannabinoids has great potential to mix with the essential mineral element, because it can support and increase the action of other drugs and medicinal substances, offering tremendous synergy. Many promising clinical studies are ongoing around the world, with cannabinoids being a key research topic for the substance abuse treatment and psychological disorders.

The 9-month human trial will study substance abuse patients who had drug prescription treatment or dietary supplement monotherapy, full-spectrum cannabinoid monotherapy, and a combination of full-spectrum cannabinoids and a dietary supplement molecule. The patient will receive this treatment sequentially. The first three months with drug prescription treatment monotherapy or dietary supplement monotherapy, the second three months with drug prescription or dietary supplement combined with full-spectrum cannabinoids, and the last 3 months with full-spectrum cannabinoids and hemp oil.  

The choice of the molecule that will be combined with the full-spectrum cannabinoids have selected after months of meticulous due diligence. The project will test the additive nature of full-spectrum cannabidnoids with two different forms of an essential mineral element, which will be revealed soon.

Should the potential synergies between the essential mineral element and cannabinoids (mainly CBD) prove successful, as the company is confident that it will, then ETST will be positioned to bring an innovative new products to the marketplace to counteract the scourge of opioid deaths that is sweeping the US. Earth Science Tech envisions and plans on producing a nutraceutical product that could be sold over the counter to help addicts resist cravings, and a cannabinoid companion for a generic drug to make the treatment more effective and reduce the danger, toxicity, and side-effects.

The Company’s CLO, Gabriel Aviles, and CEO/CSO, Dr. Michel Aube, will be supervising the project along with the medical professional advisory board team providing their resources for the human trials. The project time frame and goal is set to be completed, along with white paper studies by early 2019. This will encourage the Company to pursue clinical studies for at least two years through the remainder of 2019 and 2020, pioneering the never before attempted research studies on these two compounds combined.

ETST is currently communicating with their third-party CGMP laboratory on  mixing the anti-opioid formula for human trials, and are in talks with rehab centers interested in participating in the study to some capacity. The Company plans on sharing updates as they progress.

 

About Earth Science Tech (ETST): Earth Science Tech has among the highest quality, purity and full-spectrum high-grade hemp CBD (cannabidiol) oil on the market. Made using the superior supercritical CO2 liquid extraction, ETST’s CBD oil is 100% natural and organic. The company’s research, performed alongside the University of Central Oklahoma and DV Biologics laboratory, demonstrates that ETST is the top nutritional and dietary supplement brand for high-grade hemp CBD oil.

To learn more and to buy CBD Hemp Oil, please visit: www.earthsciencetech.com

 

About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (sexually transmitted infections and/or diseases). Earth Science Pharmaceutical CEO Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.

To learn more please visit: www.EarthSciencePharmaceutical.com

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech (ETST). Cannabis Therapeutics was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals, as well as other products & solutions. Cannabis Therapeutics’ mission it to help change the health care landscape by introducing its proprietary cannabis-cannabinoid-based products made for both the pharmaceutical and retail consumer markets worldwide.

To learn more please visit: www.CannabisThera.com

About KannaBidioiD: KannaBidioid, Inc. is wholly owned subsidiary of Earth Science Tech (ETST). KannaBidioid is focused in the recreational space to manufacture and distribute vapes/e-liquids and gummy edibles in the recreational space formulated by its unique Kanna and CBD formula. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhance focus, and help with nicotine addiction based on their properties.

To learn more please visit: www.KannaBidioiDInc.com

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Dave Demarest (305) 546-7640

Earth Science Tech Nickolas S. Tabraue, P/D/COO (305) 615-2118

Categories
Gonorrhea Latest News Marketing Medical Press Releases Sexually Transmitted Infections

ETST:Negotiations underway for MSN-2 and Nanoderm distribution in three countries and plans new clinical study with HIV- seropositive and AIDS patients

Doral, FL, Nov. 30, 2017 (GLOBE NEWSWIRE) — Earth Science Tech (OTC PINK: ETST) (“ETST” or “the Company”), an innovative biotech company that operates in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical, medical device, research and development, updated share holders on medical devices  promotion and plans to launch a clinical study with HIV-seropositive and AIDS patients

As previously announced, ETST will initiate the distribution of its medical devices in Djibouti and Morocco (http://www.otcmarkets.com/stock/ETST/news/Earth-Science-Tech–Inc–Announces-New-Agreement-with-Axcelon-Biopolymers-Corp–for-Distribution-of-Nanoderm-trade–Medical-Device–amp–Advances-with-Its-MSN-2-Medical-Device?id=170151&b=y ) while the company waits for regulatory permission to launch in North America.  ETST announces an imminent partnership agreement to develop the Vietnam market for the MSN-2 medical device (branding with original name and graphic environment is coming soon (http://www.otcmarkets.com/stock/ETST/news/Earth-Science-Tech–Inc–Signs-Contract-with-Absolu-to-Advance-Phase-2-Rollout-on-MSN-2-Medical-Device?id=166272&b=y ) and the Nanoderm™ medical device which was developed by a member of the ETST advisory board, Dr. Chandra Panchal (Founder, Chairman, Chief Executive Officer and Chief Scientific Officer of Axcelon Biopolymer: http://axcelonbp.com/companay/board-of-directors/ ). Only some details remain to be discussed and the new Vietnam market partner will be announced in the before year end.

The company is also in discussion to introduce its high-grade CBD hemp oil in the primary launch countries. The first samples of MSN-2 and Nanoderm™ are being sent to those three countries, Djibouti, Morocco and Vietnam, in order to start negotiations with local authorities and partners.

In Vietnam the products will be presented directly to hospital administrators and physicians by ETST’s new American partner who is of Vietnamese origin. This partner, whose name will be announced officially in a few days, has been a distributor of medical devices for many years and saw a huge opportunity working with us.

New clinical study of HIV seropositive and AIDS-infected patients

ETST is planning a clinical study of HIV-seropositive people and AIDS-infected patients in the hope of making as much a difference in the lives of as many people as is possible. The company sees a very good opportunity to help people that are infected with HIV because they suffer from oxidative- related stress and inflammation that are caused by their medical condition. Many HIV patients suffer from chronic pain that requires them to take opioids, or are addicted to opioids. ETST’s CBD rich hemp oil may help them to diminish the quantity of pain relief drugs they need to take and help with the withdrawal from opioids. This project is in line with the clinical study that was just announced this week (http://www.otcmarkets.com/stock/ETST/news/Earth-Science-Tech-Commences-Pre-Launch–Double-Blind-Human-Clinical-Trials-for-New-CBD-Formula-to-Fight-U-S–Opioid-Epidemic?id=176428&b=y ).

In addition, HIV patients are often afflicted by neurological complications that originate from neuro-inflammation. The neuronal protection activity of ETST CBD rich hemp oil has already been proven in vitro by DV Biologics:

http://www.otcmarkets.com/stock/ETST/news/DV-Biologics–a-Leading-Biological-Company–Reports-Earth-Science-Tech–ETST–High-Grade-Hemp-CBD–Cannabidiol–Oil-Reduces-Oxidative-Stress-and-Lipid-Peroxidation-on-Human-Brain-Cells-In-Vitro?id=107954&b=y

The administration of CBD may not only relieve many symptoms resulting from HIV infection and associated medication, but it may also help to retard the development of other HIV-associated diseases. This clinical assay will lay the foundation for the creation of the first CBD rich Hemp Oil product improved with other natural molecules to relieve symptoms and retard diseases in HIV patients.

Further updates concerning the third clinical study and other ETST projects will be issued soon.

 

About Earth Science Tech (ETST)

Earth Science Tech has the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the world’s best supercritical CO2 liquid extraction, our CBD Oil is 100% natural and organic. Our research performed alongside the University of Central Oklahoma and DV Biologics laboratory, prove we are the top nutritional and dietary supplement brand for High Grade Hemp CBD Oil.

To learn more and to buy CBD Hemp Oil please visit: www.earthsciencetech.com

View ETST’s accomplishments and reports on its High-Grade CBD Hemp Oil: (here)

 

About Earth Science Pharmaceutical

Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.

To learn more please visit: www.Earthsciencepharmaceutical.com

 

About Cannabis Therapeutics

Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide.

To learn more please visit: www.Cannabisthera.com

 

About KannaBidioiD

KannaBidioid, Inc. is wholly owned subsidiary of Earth Science Tech (ETST). KannaBidioid, Inc. is focused in the recreational space to manufacture and distribute vapes/e-liquids and gummy edibles in the recreational space formulated by it’s unique Kanna and CBD formula. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhance focus, and help with nicotine addiction based on their properties.

To learn more please visit: www.kannabidioidinc.com

 

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE

These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.

 

SAFE HARBOR ACT

Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

 

Investor Relations Dave Demarest (305)-546-7640

Earth Science Tech Nickolas S. Tabraue, P/D/COO (305)-615-2118